Supriya Lifescience Limited (IN:SUPRIYA)
:SUPRIYA
Want to see IN:SUPRIYA full AI Analyst Report?
Top Page
Supriya Lifescience Limited
(SUPRIYA)
Select Model
Select Model
Rating:73Outperform
Price Target:
₹1,022.00
▲(36.09% Upside)
Action:Reiterated
Date:06/03/26
The score is primarily supported by strong financial quality—low leverage, solid profitability, and improving cash generation—while technicals show strong momentum but extreme overbought readings increase near-term risk. Valuation is the biggest headwind due to a high P/E and very low dividend yield.
Positive Factors
Conservative balance sheet / low leverage
Very low leverage and a growing equity base provide durable financial flexibility. This reduces bankruptcy and refinancing risk, supports investment or M&A without heavy external funding, and helps the company withstand cyclical pharma demand or regulatory-driven delays over the next 2–6 months.
Negative Factors
Margin and earnings volatility
Historical swings in margins and earnings reduce predictability of profitability and make forward cashflow estimates less reliable. For a manufacturing-focused API business, variability from product mix, pricing, or cost inputs can persist and affect stakeholder planning over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Conservative balance sheet / low leverage
Very low leverage and a growing equity base provide durable financial flexibility. This reduces bankruptcy and refinancing risk, supports investment or M&A without heavy external funding, and helps the company withstand cyclical pharma demand or regulatory-driven delays over the next 2–6 months.
Read all positive factors
Supriya Lifescience Limited (SUPRIYA) vs. iShares MSCI India ETF (INDA)
Market Cap
₹74.94B
Dividend Yield0.13%
Average Volume (3M)18.01K
Price to Earnings (P/E)35.9
Beta (1Y)1.19
Revenue Growth18.86%
EPS Growth11.25%
CountryIN
Employees448
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)22.67
Shares Outstanding80,482,800
10 Day Avg. Volume18,341
30 Day Avg. Volume18,009
Financial Highlights & Ratios
PEG Ratio1.92
Price to Book (P/B)3.78
Price to Sales (P/S)5.46
P/FCF Ratio105.21
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)30.5
Revenue Forecast (FY)₹9.94B
Supriya Lifescience Limited Business Overview & Revenue Model
Company Description
Supriya Lifescience Ltd. is an Indian pharmaceutical enterprise, established in 1987 and headquartered in Mumbai. The company's primary business involves the global research, development, manufacturing, and commercialization of Active Pharmaceutic...
How the Company Makes Money
Supriya Lifescience primarily makes money by manufacturing APIs and selling them to pharmaceutical companies and other formulators that use these ingredients to produce finished drugs. Revenue is generated from (1) sale of APIs across its product ...
Supriya Lifescience Limited Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
92
Very Positive
Cash Flow
70
Positive
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.15B | 8.28B | 6.96B | 5.70B | 4.51B | 5.19B |
| Gross Profit | 4.83B | 4.49B | 3.84B | 2.80B | 2.80B | 2.89B |
| EBITDA | 2.68B | 2.94B | 2.71B | 1.84B | 1.37B | 2.22B |
| Net Income | 1.82B | 2.09B | 1.88B | 1.19B | 898.57M | 1.52B |
Balance Sheet | ||||||
| Total Assets | 12.03B | 13.57B | 11.12B | 9.21B | 8.20B | 7.35B |
| Cash, Cash Equivalents and Short-Term Investments | 1.06B | 788.67M | 791.54M | 749.56M | 1.58B | 2.25B |
| Total Debt | 52.32M | 54.35M | 53.80M | 54.88M | 224.68M | 274.15M |
| Total Liabilities | 1.21B | 1.59B | 1.16B | 1.06B | 1.21B | 1.19B |
| Stockholders Equity | 10.82B | 11.98B | 9.97B | 8.15B | 6.99B | 6.16B |
Cash Flow | ||||||
| Free Cash Flow | 133.16M | 429.88M | 101.89M | -323.48M | -422.13M | -111.03M |
| Operating Cash Flow | 555.65M | 1.95B | 1.73B | 1.13B | 661.87M | 488.01M |
| Investing Cash Flow | -304.29M | -1.88B | -1.62B | -1.74B | -1.33B | -598.22M |
| Financing Cash Flow | -10.75M | -79.93M | -65.47M | -223.59M | -97.77M | 1.50B |
Supriya Lifescience Limited Technical Analysis
Positive
751.00
Price Trends
777.20
Positive
708.54
Positive
719.65
Positive
Market Momentum
47.61
Positive
57.70
Neutral
21.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Positive. The current price of 751 is below the 20-day moving average (MA) of 922.33, below the 50-day MA of 777.20, and above the 200-day MA of 719.65, indicating a bullish trend. The MACD of 47.61 indicates Positive momentum. The RSI at 57.70 is Neutral, neither overbought nor oversold. The STOCH value of 21.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:SUPRIYA.
Supriya Lifescience Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
73 Outperform | ₹74.94B | 35.89 | ― | 0.13% | 18.86% | 11.25% | |
64 Neutral | ₹88.93B | 35.76 | ― | 0.22% | -8.03% | -18.80% | |
58 Neutral | ₹26.78B | 27.30 | ― | ― | 8.13% | 2910.16% | |
58 Neutral | ₹32.79B | -647.40 | ― | ― | 14.43% | 35.48% | |
54 Neutral | ₹184.28B | -257.12 | ― | ― | 47.33% | 57.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ₹39.66B | -59.13 | ― | 0.06% | 83.86% | -14.25% |
* Healthcare Sector Average
IN:SUPRIYA
Supriya Lifescience Limited
926.95
255.12
37.97%
IN:BLUEJET
Blue Jet Healthcare Limited
521.30
-331.90
-38.90%
IN:DCAL
Dishman Carbogen Amcis Ltd.
173.25
-68.60
-28.36%
IN:PANACEABIO
Panacea Biotec Limited
524.75
109.75
26.45%
IN:ZOTA
Zota Health Care Ltd.
1,369.40
438.30
47.07%
IN:ONESOURCE
OneSource Specialty Pharma Limited
1,613.15
-330.35
-17.00%
Supriya Lifescience Limited Corporate Events
Supriya Lifescience Publishes Postal Ballot Notice in Newspapers
Mar 11, 2026
Supriya Lifescience Limited notified the stock exchanges that it has published a notice of postal ballot in major newspapers as part of its regulatory obligations. The advertisement appeared on 11 March 2026 in the Financial Express and Loksatta, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.